Incyte Analyst Ratings
Incyte Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
Incyte Analyst Ratings
Incyte's Share Buyback Program: A Buy Rating and Fundamental Value Increase
Incyte's Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Incyte Analyst Ratings
Citigroup Adjusts Price Target on Incyte to $80 From $81
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained
Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Incyte Analyst Ratings
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
Incyte (INCY) Gets a Buy From Piper Sandler
Incyte Analyst Ratings